Epilepsy,Seizures Epilepsy
Conditions
Interventions
We will include people (all ages) who had or have implanted DBS electrodes since 2013, and people who will get DBS electrodes implanted in the future.
Sponsors
Stichting Epilepsie Instellingen Nederland (SEIN)
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: implanted DBS (deep brain stimulation) electrodes
Exclusion criteria
Exclusion criteria: no informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Data will be collected for future research around DBS therapy. The exact purpose is not known at this time. The most important endpoint will be effective DBS therapy, defined as percentual seizure change compared to baseline before DBS therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study endpoints are other parameters that are important for the patient and neurologist to define an effective DBS therapy, for instance:Percentual reduction of the frequency of use of emergency medication to stop seizures. Number of hospital admissionsSide effects (such as depression/mood swings)Medication withdrawalAdverse events | — |
Countries
Netherlands
Contacts
Public ContactS.B. Jelsma
Stichting Epilepsie Instellingen Nederland (SEIN)
Outcome results
None listed